WHWK
Whitehawk Therapeutics Inc
$
1.690
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.750
Open
1.750
VWAP
1.72
Vol
53.99K
Mkt Cap
80.59M
Low
1.660
Amount
92.63K
EV/EBITDA(TTM)
--
Total Shares
47.13M
EV
-94.73M
EV/OCF(TTM)
--
P/S(TTM)
3.31
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Show More
2 Analyst Rating
18.34% Upside
Wall Street analysts forecast WHWK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WHWK is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
18.34% Upside
Current: 1.690
Low
2.00
Averages
2.00
High
2.00
18.34% Upside
Current: 1.690
Low
2.00
Averages
2.00
High
2.00
The End
See All Ratings
No Data
Valuation Metrics
The current forward P/E ratio for Whitehawk Therapeutics Inc (WHWK.O) is -1.00, compared to its 5-year average forward P/E of -2.61. For a more detailed relative valuation and DCF analysis to assess Whitehawk Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.61
Current PE
-1.00
Overvalued PE
-2.06
Undervalued PE
-3.16
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.14
Current PS
0.00
Overvalued PS
3.15
Undervalued PS
1.14
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+251.32%
-54.75M
Operating Profit
FY2025Q2
YoY :
+260.80%
-52.62M
Net Income after Tax
FY2025Q2
YoY :
+40.74%
-0.76
EPS - Diluted
FY2025Q2
YoY :
+446.07%
-52.96M
Free Cash Flow
FY2025Q2
YoY :
+2.23%
89.36
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
YoY :
-220.98%
285.53
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 230.74% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.5M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
7.6M
Volume
Months
6-9
1
2.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
WHWK News & Events
Events Timeline
2025-03-31 (ET)
2025-03-31
17:33:15
Whitehawk Therapeutics files to sell 41.67M shares of common stock for holders
Sign Up For More Events
Sign Up For More Events
News
9.5
08-07PRnewswireWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
1.0
07-22PRnewswireWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
1.0
06-19NewsfilterWhitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
Sign Up For More News
People Also Watch
META
Meta Platforms Inc
765.870
USD
-0.45%
AMZN
Amazon.com Inc
221.300
USD
-0.62%
AAPL
Apple Inc
227.180
USD
-0.95%
TSLA
Tesla Inc
339.030
USD
+2.85%
MSFT
Microsoft Corp
521.770
USD
-0.05%
NVDA
NVIDIA Corp
182.060
USD
-0.35%
AVGO
Broadcom Inc
303.900
USD
-0.35%
ORCL
Oracle Corp
252.680
USD
+1.05%
XOM
Exxon Mobil Corp
105.830
USD
-0.91%
WMT
Walmart Inc
103.930
USD
+0.19%
FAQ
What is Whitehawk Therapeutics Inc (WHWK) stock price today?
The current price of WHWK is 1.69 USD — it has decreased -3.43 % in the last trading day.
What is Whitehawk Therapeutics Inc (WHWK)'s business?
What is the price predicton of WHWK Stock?
What is Whitehawk Therapeutics Inc (WHWK)'s revenue for the last quarter?
What is Whitehawk Therapeutics Inc (WHWK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Whitehawk Therapeutics Inc (WHWK)'s fundamentals?
How many employees does Whitehawk Therapeutics Inc (WHWK). have?